




# Gene Editing for neXt-CP50 and neXt-MP50 challenges

**Katerina Poverennaya, Leonid Kurbatov, Andrey Lisitsa**

INSTITUTE OF BIOMEDICAL CHEMISTRY  
MOSCOW, RUSSIA

[www.ibmc.msk.ru](http://www.ibmc.msk.ru)


# HISTORY OF GENE EDITING




# COMPARISON OF METHODS

	ZNFs	TALENs	CRISPR-Cas9
<b>Target site length</b>	18-36 bp per ZNF pair	28-40 bp per TALEN pair	19-22 bp
<b>Off-target effects</b>	Some mismatches are tolerated	Some mismatches are tolerated	Tolerant even of several mismatches
<b>Targeting constraints</b>	G-rich regions are challenging	5'T for each TALEN is required	PAM is required
<b>Ease of design</b>	Difficult	Moderate	Easy
<b>Multiplexing</b>	Challenging	Challenging	Easy
<b>Ease of <i>in vivo</i> delivery</b>	Small size allows use of many viral vectors	Large size of each TALEN limits viral vectors	<i>S. Pyogenes</i> Cas9 is too large for smaller capacity viral vector
<b>Ease of <i>ex vivo</i> delivery</b>	Relatively easy	Relatively easy	Respectively easy


# SCHEME of CRISPR-Cas9 TECHNOLOGY



# EXPLORATION OF BIOLOGICAL INFORMATION




# APPLICATION FOR C-HPP



challenge	knock-out	knock-down	knock-in	tagging
neXt-MP50	-	-	+	+
neXt-CP50	+	+	+	+

# FUNCTIONAL ANNOTATION (PPI): INSERT TAG


TRANSCRIPTOME → prevailing transcript of target gene  
GENOME → searching primers



# GENE EDITING + AP-MS

*transfection*

*Plasmid 1*  
(with guideRNA-Cas9 complex)









*Plasmid 2*  
(with changed sequence)





*selection*

*growing*




*MS-analysis*

*antibody*



*fish*

# FUNCTION: GUILT-BY-ASSOCIATION





THANK YOU  
FOR ATTENTION!

**Monument to the laboratory mouse editing DNA itself.**  
Akademgorodok, Novosibirsk, Russia